ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2000, 'PROGRESS (Perindopril Protection Against Recurrent Stroke Study): Regional characteristics of the study population at baseline', Journal of Hypertension, Supplement, 18
,2000, 'Differences between blood-pressure-lowering drugs', Lancet, 356, pp. 352 - 353, http://dx.doi.org/10.1016/S0140-6736(00)02521-6
,2000, 'Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial', Lancet, 355, pp. 1295 - 1302, http://dx.doi.org/10.1016/S0140-6736(00)02110-3
,2000, 'A systematic survey of 13 randomized trials of non-steroidal anti-inflammatory drugs for the prevention of heterotopic bone formation after major hip surgery', Acta Orthopaedica Scandinavica, 71, pp. 122 - 128, http://dx.doi.org/10.1080/000164700317413076
,2000, 'No effect of low-dose aspirin for the prevention of heterotopic bone formation after total hip replacement: A randomized trial of 2,649 patients', Acta Orthopaedica Scandinavica, 71, pp. 129 - 134, http://dx.doi.org/10.1080/000164700317413085
,2000, 'Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty.', Cochrane database of systematic reviews (Online)
,2000, 'UNDER THE MICROSCOPE', Evidence-based Cardiovascular Medicine, 4, pp. 28 - 30, http://dx.doi.org/10.1054/ebcm.2000.0286
,1999, 'Determinants of cardiovascular disease in the Asian Pacific Region: Protocol for a collaborative overview of cohort studies', CVD Prevention, 2, pp. 281 - 289
,1999, 'Less salt does not necessarily mean less taste', Lancet, 353, pp. 1332, http://dx.doi.org/10.1016/S0140-6736(99)01198-8
,1999, '1999 World Health Organization International Society of Hypertension guidelines for the management of hypertension', JOURNAL OF HYPERTENSION, 17, pp. 151 - 183, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000079235700001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,1999, '1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension', Blood Pressure, Supplement, 8, pp. 9 - 43
,1999, 'PROGRESS - Perindopril Protection Against Recurrent Stroke Study: Characteristics of the study population at baseline', Journal of Hypertension, 17, pp. 1647 - 1655
,1999, 'The world health organization- international society of hypertension blood pressure lowering treatment trialists' collaboration: Prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments', Current Hypertension Reports, 1, pp. 346 - 356, http://dx.doi.org/10.1007/s11906-999-0045-2
,1999, 'Captopril and conventional treatment had similar effects on cardiovascular morbidity and mortality in patients with primary hypertension', Evidence-based Cardiovascular Medicine, 3, pp. 74 - 74, http://dx.doi.org/10.1054/ebcm.1999.0232
,1998, 'Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments', Journal of Hypertension, 16, pp. 127 - 137
,1998, 'Blood pressure and the risk of recurrent vascular disease', American Journal of Hypertension, 11, pp. 25A - 25A, http://dx.doi.org/10.1016/s0895-7061(97)90792-5
,1997, 'Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding', Hypertension Research - Clinical and Experimental, 20, pp. 61 - 72
,1997, 'Blood pressure lowering for the secondary prevention of myocardial infarction and stroke', Hypertension, 29, pp. 537 - 538, http://dx.doi.org/10.1161/01.HYP.29.2.537
,1997, 'Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding', Journal of Human Hypertension, 11, pp. 331 - 342, http://dx.doi.org/10.1038/sj.jhh.1000467
,1996, 'Forty years of randomised trials in the New Zealand Medical Journal', New Zealand Medical Journal, 109, pp. 372 - 373
,1996, 'Blood pressure lowering in patients with cerebrovascular disease: Results of the progress (perindopril protection against recurrent stroke study) pilot phase', Clinical and Experimental Pharmacology and Physiology, 23, pp. 444 - 446, http://dx.doi.org/10.1111/j.1440-1681.1996.tb02758.x
,1995, 'PROGRESS (perindopril protection against recurrent stroke study): rationale and design. PROGRESS Management Committee [corrected]', Journal of hypertension, 13, pp. 1869 - 1873
,1995, 'The PROGRESS study: Rationale and design', Journal of Hypertension, 13, pp. 1869 - 1873, http://dx.doi.org/10.1097/00004872-199512010-00068
,